title: AC133+ umbilical cord blood progenitors demonstrate rapid self-renewal and low apoptosis.
abstract: Umbilical cord blood (UCB) provides immediate access to haemopoietic stem/progenitor cells (HSPC) but low cell number restricts use in full adult bone marrow reconstitution. This study investigated early ex vivo expansion kinetics of UCB AC133+ cells (2-4 x 10(4)/ml), mononuclear cells (MNC, 1-2 x 10(6)/ml) and AC133negative cells (AC133(neg), 2-4 x 10(4)/ml) in stroma-free 8 d liquid culture (fetal bovine serum-supplemented Iscove's-modified Dulbecco's medium (IMDM) with either 'K36EG'[c-Kit ligand, interleukin 3 (IL-3), IL-6, erythropoietin, granulocyte colony-stimulating factor] or 'TPOFL' (thrombopoietin, Flt-3 ligand). Cell enumeration, apoptosis assay and AC133/CD34/CD38 antigen immunophenotyping were performed at d 0, 3, 5 and 8. All three cell populations went through a proliferation lag phase between d 3 and d 5. AC133+ cells recovered better from lag phase with significantly higher fold increase (FI) when compared with MNC and AC133(neg) populations (K36EG FI: 15.04 +/- 5.46; TPOFL FI: 8.59 +/- 2.92, P < 0.05). After 8 d, populations lacking AC133+ cells were significantly more inclined to undergo apoptosis under proliferative conditions (P < 0.01). Also, when compared with K36EG, 8 d TPOFL-expanded AC133+ cells encompassed a significantly higher percentage of AC133+ and CD34+ early HSPC (K36EG: 20.50 +/- 2.36; TPOFL: 47.00 +/- 7.69; P < 0.05). In conclusion, TPOFL synergism demonstrated the potential for AC133+ HSPC ex vivo expansion inducing self-renewal, early HSPC maintenance and promoting cell survival status.
authors.affiliation: King-George Laboratory, St George's Hospital Medical School and Kingston University, London, UK.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Forraz
authors.forename: Ruth
authors.initials: R
authors.lastname: Pettengell
authors.forename: Pierre-Antoine
authors.initials: PA
authors.lastname: Deglesne
authors.forename: Colin P
authors.initials: CP
authors.lastname: McGuckin
mesh_terms: D000071916:AC133 Antigen; D036541:ADP-ribosyl Cyclase / Q000276:immunology; D051997:ADP-ribosyl Cyclase 1; D015703:Antigens, CD / Q000276:immunology; D018952:Antigens, CD34 / Q000276:immunology; D017209:Apoptosis; D002455:Cell Division; D002469:Cell Separation; D002478:Cells, Cultured; D005312:Fetal Blood; D005434:Flow Cytometry; D006023:Glycoproteins / Q000276:immunology*; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000276:immunology*; D006801:Humans; D008562:Membrane Glycoproteins; D008565:Membrane Proteins / Q000494:pharmacology; D010455:Peptides / Q000276:immunology*; D013926:Thrombopoietin / Q000494:pharmacology
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D018952:Antigens, CD34; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; C000606023:PROM1 protein, human; D010455:Peptides; C084881:flt3 ligand protein; D013926:Thrombopoietin; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1